Vladimir Makatsaria

Chief Executive Officer at LivaNova

Board

Since March 1, 2024

Age

51 years

Education

Holds a Bachelor of Arts in Physiology, a Master of Business Administration (MBA), and a Master of Healthcare Administration from the University of Minnesota.

Tenure

Became Chief Executive Officer and joined the Board of Directors of LivaNova on March 1, 2024.

Also at LivaNova

Alex Shvartsburg

Chief Financial Officer

Michael Hutchinson

Chief Legal Officer

Stephanie Bolton

President, Global Epilepsy

About

Vladimir A. Makatsaria is the Chief Executive Officer and a member of the Board of Directors at LivaNova PLC, having assumed these roles on March 1, 2024. At 51 years old, he brings extensive leadership experience from a 27-year career at Johnson & Johnson, where he held multiple executive roles including Company Group Chairman at J&J MedTech.

Prior to joining LivaNova, his career encompassed key positions such as Chairman of J&J China, Global Integration Leader for J&J Medical Devices, and President of Ethicon and Emerging Markets. His proven ability to drive innovation and results in the healthcare sector has defined his reputation as a transformative leader.

Beyond his corporate roles, he has contributed to the industry by serving as Chairman of the Asia Pacific Medical Technology Association (APACMed) and as an Advisory Board Member to Singapore Management University. His diverse experience and strategic expertise continue to make a significant impact in advancing global healthcare solutions.

$LIVN Performance Under Vladimir Makatsaria

Past Roles

Organization	Role	Date Range	Details
Johnson & Johnson	Company Group Chairman at J&J MedTech	N/A [N/A]	Led Ethicon and served in various executive leadership roles over 27 years
Johnson & Johnson	Leader of J&J China	N/A [N/A]	Executed leadership responsibilities for the China market
Johnson & Johnson	Leader of J&J MedTech APAC	N/A [N/A]	Oversaw MedTech operations in the Asia-Pacific region
Johnson & Johnson	Leader of Ethicon EMEA	N/A [N/A]	Directed Ethicon’s operations in Europe, the Middle East, and Africa
Asia Pacific Medical Technology Association (APACMed)	Chairman of the Board	N/A [N/A]	Oversaw board responsibilities for the APAC medical technology community
Singapore Management University	Advisory Board Member	N/A [N/A]	Provided strategic advice; not an academic position

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$930,000	Annualized	Fixed base salary
Sign-On Cash Bonus	$200,000	One-time	Awarded upon joining
Relocation Benefits	N/A	As provided	Assistance with relocation from NYC to Houston; no amount specified

Performance Compensation

Data from FY 2024

Annual Bonus

Component	Target Amount	Threshold / Maximum Opportunity	Vesting / Payout Conditions	Additional Details
Annual Bonus	110% of Base Salary (~$1,023,000 based on $930,000)	Up to 200% of Base Salary (~$1,860,000)	Payout based on achieving financial and non‑financial performance targets as set by the Compensation & HCM Committee	No further breakdown provided

Long-Term Equity Incentive Awards (LTIP)

Component	Grant Date Fair Value	Weight	Vesting Schedule	Performance Metric & Thresholds	Additional Details
PSUs	$2,675,000	50%	Cliff vesting on March 30, 2026	ROIC measured over 2024–2026 with thresholds:<br>- Target: 100%<br>- Target +125 bps: 150%<br>- Target +250 bps: 200%<br>- Target –125 bps: 50%<br>- Target –250 bps: 0%	Performance-based vesting
RSUs	$1,337,500	25%	Equal installments over 4 years	Time-based vesting; no performance metric applied	–
SARs	$1,337,500	25%	Equal installments over 4 years	Time-based vesting; no performance metric applied	–

Special Inducement Equity Grants

Component	Grant Date Fair Value	Vesting Schedule	Performance Metric	Additional Details
Special Inducement Equity	$1,500,000	Equal annual installments over 4 years	None (time‑based)	No performance metrics or thresholds provided